Announcement • Apr 29
Epsilon Healthcare Limited, Annual General Meeting, May 29, 2026 Epsilon Healthcare Limited, Annual General Meeting, May 29, 2026. Location: at offices of baker mckenzie, level 32, riparian plaza, 71 eagle street, brisbane,queensland, 4000 Australia Announcement • Nov 20
Epsilon Healthcare Limited, Annual General Meeting, Dec 22, 2025 Epsilon Healthcare Limited, Annual General Meeting, Dec 22, 2025. Location: offices of baker mckenzie, level 32, 71 eagle street, brisbane, queensland 4000, Australia Announcement • Jul 09
Epsilon Healthcare Announces Appointment of Daniel Kaplon as Chief Financial Officer, Effective 8 July 2025 Epsilon Healthcare announced the appointment of Mr. Daniel Kaplon to the role of Chief Financial Officer, effective 8 July 2025. Daniel Kaplon will report directly to Mr. Giannopoulos. Mr. Kaplon is a Chartered Accountant and seasoned executive with over 25 years' experience spanning finance, operations, and commercial leadership roles across ASX-listed and private companies in healthcare, health technology, and manufacturing. Notably, he was recently CFO at an ASX listed small cap digital health company and has held senior leadership roles at Ramsay Health Care in its pharmacy division and served as CFO/COO at MediSecure, an electronic prescription exchange service. Daniel holds an undergraduate honours degree in Commerce, a business degree in Transport and Logistics Management, and a Master of Entrepreneurship and Innovation (MEI), during which he co-founded two medical device start-ups. The Announcement has been approved by the full Board of the Company. Announcement • Apr 28
Epsilon Healthcare Limited, Annual General Meeting, May 28, 2025 Epsilon Healthcare Limited, Annual General Meeting, May 28, 2025. Location: offices of baker mckenzie, level 32, riparian plaza, 71 eagle street, brisbane, queensland, 4000, Australia Announcement • Dec 27
Epsilon Healthcare Limited has completed a Follow-on Equity Offering in the amount of AUD 0.72 million. Epsilon Healthcare Limited has completed a Follow-on Equity Offering in the amount of AUD 0.72 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,000,000
Price\Range: AUD 0.016
Transaction Features: Subsequent Direct Listing Announcement • Dec 19
Epsilon Healthcare Limited has filed a Follow-on Equity Offering in the amount of AUD 0.72 million. Epsilon Healthcare Limited has filed a Follow-on Equity Offering in the amount of AUD 0.72 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,000,000
Price\Range: AUD 0.016
Transaction Features: Subsequent Direct Listing Announcement • Aug 20
Epsilon Healthcare Appoints Richard Legge as Company Secretary Epsilon Healthcare announced the appointment of Mr. Richard Legge, Director Audit & Assurance Services at Ure Lynam & Co as Company Secretary effective immediately. Legge brings significant Company Secretarial experience, in addition to a deep understanding of audit and assurance processes, which will assist the Epsilon Board in preparing for their future development plans. Legge will also play an important role in supporting the Board in undertaking activities required by the Australian Securities Exchange (ASX) as it works towards an orderly lifting of the suspension of trading in the Company's securities at the appropriate time when it has satisfied the ASX that remedial actions have been undertaken. The Epsilon Board would like to sincerely thank Mr. Marcelo Mora for his contributions as the Company Secretary during his tenure. Mr. Mora's approach to his service to the Company and the Board during what has been a tumultuous and challenging time is acknowledged and appreciated. Announcement • Jul 08
Epsilon Healthcare Limited Announces Termination of Xiao (Josh) Cui as Company Secretary Epsilon Healthcare Limited announced that the services of Mr. Xiao (Josh) Cui as Company Secretary of Epsilon has been terminated effective immediately and Mr. Marcelo Mora continues to be Company Secretary of Epsilon. Announcement • Dec 03
Epsilon Healthcare Receive Notice from Watercrest Asset Management Pty Ltd On December 1, 2023, Epsilon Healthcare Limited announced that it has received notice from Watercrest Asset Management Pty Ltd (Requisitioning Shareholder) that on November 21, 2023, the Requisitioning Shareholder notified the Company to propose a resolution at a general meeting for the removal of Alan Preston Beasley from the board of directors of the Company under section 203D of the Corporations Act 2001 and on November 23, 2023, the Requisitioning Shareholder requested the Company convene a general meeting of shareholders under section 249D of the Act. In addition, the Company has taken external legal advice in relation to the validity of the Section 203D Notice and the Section 249D Notice and has confirmed that the Company are valid in each case and the directors of the Company are required to call a general meeting within 21 days after a request under section 249D of the Act is given to the Company and to hold that meeting within two months after receipt of that request. Announcement • Dec 01
Epsilon Healthcare Limited Announces Board Appointments Epsilon Healthcare Limited announced the appointment of Mr. John Few as a non-executive director of the company effective from 30 November 2023. John Few is a dedicated business professional with a proven track record of achieving company goals through consistent and organised practices. Known for thriving under pressure, adapting to new challenges, and enhancing organizational brands, John is skilled in budget control, staff management, project management, business development and strategic planning. In his current role as the Director at East West Advisory in Sydney since February 2015, John oversees operations, collaborates with organizational leadership and the board of directors to guide operational strategy, and manages daily operations across multiple locations. He has a successful track record of establishing departmental performance goals, providing corrective feedback, and forming strategic partnerships to drive business development. John meticulously evaluates company documentation to ensure alignment with regulatory requirements. Before his current role, John served as the Operations Manager at IBM Australia from February 2002 to January 2015. During this period, he demonstrated independence and collaborative teamwork in operations management, showcasing a proven ability to learn quickly, adapt to new situations, and efficiently manage time in fast-paced environments. In a team setting, John provided support and guidance, displaying respect, friendliness, and a willingness to help, contributing to the overall success of the team. The company also announced the appointment of Mr. Josh Cui as Executive Chairman of the company effective on 30 November 2023. Mr. Cui's consultancy agreement as Executive Chairman will be $240,000 per annum (plus GST) from 1 December 2023. Mr. Cui's leadership roles have showcased his strategic acumen and unwavering commitment to excellence. He has guided organizations to success, delivering innovative, high-quality projects that have positioned his success in the industry. His fund-raising abilities have fuelled the growth of his companies. Announcement • Nov 21
Epsilon Healthcare Limited Announces Terminates Peter Giannopoulos as Chief Executive Officer Epsilon Healthcare Limited announced that effective immediately 21 November 2023, terminates Mr. Peter Giannopoulos as the role of the Chief Executive Officer. Mr. Giannopoulos did not complete his probationary period. This decision aligns with the terms and conditions outlined in the employment contract, specifically regarding the clause Probation. In the interim, Mr. Daniel Sanghera, General Manager at Epsilon Pharma will become the interim CEO. Announcement • May 19
Epsilon Healthcare Appoints Peter Giannopoulos as Chief Executive Officer, Effective 23 May, 2023 Epsilon Healthcare announced that Mr. Peter Giannopoulos has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on 23 May, 2023. Giannopoulos brings to Epsilon, more than 25 years experience across the Australian healthcare ecosystems including proven success within the ASX healthcare setting and demonstrable success in leadership, operations, M&A, GMP manufacturing & the delivery of innovative revenue, and market accretive opportunities. Most recently Peter was CEO of Cell Therapies Pty Ltd. At Cell Therapies, Peter introduced corporate strategies and controls and a trajectory for growth, including undertaking capital raising activities to support the organisation to achieve significant revenue growth in coming years as it capitalises on local and global manufacturing opportunities in the cell and gene therapy landscape. Prior to Cell Therapies Pty Ltd, Peter led the diversification of Australia's largest private hospital provider, Ramsay Healthcare as the CEO of the Ramsay Pharmacy Group over a 12 year period. As the executive who developed and led the expansion of the Ramsay Pharmacy Group from a single site in 2007, under Peter's leadership, the group operations expanded exponentially to become a multi-site operation (90 sites) generating revenues of more than AUD 400 million. Peter also has a clinical background with a degree in pharmacy and a deep understanding of the Australian and international health landscapes. Peter has forged a career in leading businesses to identify opportunities for diversification, growth and to realise long term profitability amidst a dynamic healthcare landscape. With a deep understanding of financial and operational governance developed and honed within an ASX healthcare setting, Peter seeks to optimise business processes and create accountable, scalable, sustainable and competitive organisations. 
